AMGNAmgenFinished
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Chemotherapy-induced Thrombocytopenia
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 165 (final count)
- Started
- Sep 30, 2019
- Main results expected
- Jan 25, 2024
- Fully finished
- Jan 9, 2025
- Results posted
- Feb 11, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification
Measured over: Day 1 up to Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03362177 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC